<DOC>
	<DOCNO>NCT01358825</DOCNO>
	<brief_summary>The aim study ass antibody persistence infant receive three dos Infanrix hexa™ ( DTPa-HBV-IPV/Hib ) Infanrix-IPV/Hib™ ( DTPa-IPV/Hib ) 3 , 5 11 month age study NCT00307034 .</brief_summary>
	<brief_title>Study Evaluate Antibody Persistence Children Previously Vaccinated With Infanrix Hexa™ Infanrix-IPV/Hib™</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Subjects receive 3 dos Infanrix hexa™ InfanrixIPV/Hib™ study NCT00307034 . Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) LAR ( ) comply requirement protocol . A male female subject age 5 year time study entry . Written inform consent obtain parent ( ) /LAR ( ) subject . Healthy subject establish medical history clinical examination enter study . Child care . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Use investigational nonregistered product within 30 day prior blood sampling . Evidence previous intercurrent diphtheria , tetanus , pertussis , polio , hepatitis B , Hib vaccination disease since study NCT00307034 , exception hepatitis B vaccination DTPaIPV/Hib group . Administration immunoglobulins and/or blood product within 3 month prior blood sample . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Family history congenital hereditary immunodeficiency .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Infanrix-IPV/Hib</keyword>
	<keyword>Long-term follow</keyword>
	<keyword>Persistence</keyword>
	<keyword>Infanrix hexa</keyword>
</DOC>